Literature DB >> 25576860

Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014.

Jean-Michel Pawlotsky1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25576860     DOI： 10.1053/j.gastro.2015.01.002

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  21 in total

1.  Therapy: Avoiding treatment failures associated with HCV resistance.

Authors:  Jean-Michel Pawlotsky
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-27       Impact factor: 46.802

Review 2.  Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

Authors:  Sabrina Bagaglio; Caterina Uberti-Foppa; Giulia Morsica
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

Review 3.  Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy.

Authors:  L B Dustin; B Bartolini; M R Capobianchi; M Pistello
Journal:  Clin Microbiol Infect       Date:  2016-08-31       Impact factor: 8.067

4.  Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice.

Authors:  Hervé Lerat; Mohamed Rabah Imache; Jacqueline Polyte; Aurore Gaudin; Marion Mercey; Flora Donati; Camille Baudesson; Martin R Higgs; Alexandre Picard; Christophe Magnan; Fabienne Foufelle; Jean-Michel Pawlotsky
Journal:  J Biol Chem       Date:  2017-05-30       Impact factor: 5.157

5.  Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.

Authors:  Stéphanie B N Serre; Sanne B Jensen; Lubna Ghanem; Daryl G Humes; Santseharay Ramirez; Yi-Ping Li; Henrik Krarup; Jens Bukh; Judith M Gottwein
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

6.  Evidence for deleterious hepatitis C virus quasispecies mutation loads that differentiate the response patterns in IFN-based antiviral therapy.

Authors:  Yi Ren; Weihua Wang; Xiaoan Zhang; Yanjuan Xu; Adrian M Di Bisceglie; Xiaofeng Fan
Journal:  J Gen Virol       Date:  2015-11-18       Impact factor: 3.891

7.  Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors.

Authors:  Long V Pham; Santseharay Ramirez; Thomas H R Carlsen; Yi-Ping Li; Judith M Gottwein; Jens Bukh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

8.  Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.

Authors:  Yoshiki Koizumi; Hirofumi Ohashi; Syo Nakajima; Yasuhito Tanaka; Takaji Wakita; Alan S Perelson; Shingo Iwami; Koichi Watashi
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-07       Impact factor: 11.205

Review 9.  Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.

Authors:  Matthias Götte; Jordan J Feld
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-05-05       Impact factor: 46.802

10.  Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus.

Authors:  Isabel Gallego; Julie Sheldon; Elena Moreno; Josep Gregori; Josep Quer; Juan Ignacio Esteban; Charles M Rice; Esteban Domingo; Celia Perales
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.